Financial Performance - The company's revenue for Q3 2024 reached ¥485,143,734.52, representing a 53.16% increase compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was -¥281,813,873.94, with a year-to-date net profit of -¥926,768,557.18[3]. - The company's revenue for the first three quarters of 2024 reached approximately RMB 1.27 billion, representing a year-on-year increase of about 29% compared to RMB 986.46 million in the same period of 2023[15]. - Total revenue from sales of goods and services for the first three quarters of 2024 was ¥1,334,950,275.33, up from ¥994,903,657.69 in the same period of 2023, reflecting a growth of 34.3%[19]. - The company reported a total comprehensive loss of -¥1,036,670,389.84 for Q3 2024, compared to -¥1,605,861,657.78 in Q3 2023, marking a 35.3% reduction in comprehensive losses[18]. - The net profit for Q3 2024 was -¥988,725,690.94, an improvement from -¥1,555,128,891.35 in Q3 2023, representing a 36.4% reduction in losses[18]. - Operating profit for Q3 2024 was -¥969,121,005.27, compared to -¥1,580,362,717.66 in the same period last year, indicating a 38.5% improvement[18]. Research and Development - Research and development (R&D) expenses totaled ¥327,892,775.06 for the quarter, accounting for 67.59% of revenue, a decrease of 34.07 percentage points year-on-year[4]. - The company is focusing on cost control and resource allocation towards high-potential R&D projects, leading to a reduction in losses[13]. - Research and development expenses decreased to ¥874,268,925.53 from ¥1,270,626,649.07, a reduction of approximately 31.1% year-over-year[18]. - The company plans to accelerate the development and application for late-stage pipelines, including anti-tumor monoclonal antibodies and other innovative drugs[13]. - The company has received regulatory approval for the launch of the anti-PCSK9 monoclonal antibody, which is expected to enhance its product portfolio[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,498[8]. - The total number of ordinary shareholders reached 29,489 as of the end of the reporting period[10]. - The top 10 shareholders hold a total of 38,594,237 shares, representing 3.92% of the total shares[11]. - HKSCC NOMINEES LIMITED is the largest shareholder with 219,291,210 shares, accounting for 22.25%[9]. - The company has no shareholders participating in margin trading or securities lending as of the reporting period[10]. - The shareholding structure indicates that 熊俊 and 熊凤祥 are the controlling shareholders, with 熊俊 being the actual controller[10]. - The top 10 unrestricted circulating shareholders collectively hold 42,112,468 shares, which is 4.27% of the total shares[11]. - There were no changes in the top 10 shareholders due to securities lending or borrowing activities compared to the previous period[12]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥1,113,472,084.61 year-to-date[3]. - Cash flow from operating activities showed a net outflow of -¥1,113,472,084.61, an improvement from -¥1,664,114,192.65 in Q3 2023[20]. - The company reported a total cash and cash equivalents balance of RMB 3.045 billion, indicating a strong liquidity position[13]. - The cash and cash equivalents at the end of Q3 2024 were ¥2,474,334,261.64, down from ¥4,141,718,242.77 at the end of Q3 2023[20]. - The company's investment activities resulted in a net cash outflow of -¥1,083,510,749.67 for Q3 2024, compared to -¥653,834,246.14 in Q3 2023, reflecting increased investment activities[20]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥10,857,613,524.70, down 4.28% from the previous year[4]. - The total liabilities as of September 30, 2024, amounted to RMB 4.578 billion, an increase from RMB 4.022 billion at the end of 2023[15]. - The weighted average return on net assets was -4.45%, an increase of 0.46 percentage points compared to the previous year[4]. Future Outlook - The report does not provide specific future outlook or performance guidance[12]. - The company has not disclosed any new product or technology developments in this report[12]. - The company achieved significant milestones in clinical trials for its core product, Tuoyi®, contributing to improved revenue performance[7].
君实生物(01877) - 2024 Q3 - 季度业绩